BOJU SANGEETHA LAKSHMİ, BHUKYA VİDYA, MOGİLİ HARİ KRİSHNA REDDY, ANİL CHENİ VENKATA KUMAR, RAPUR RAM, VİSHNUBOTLA SİVA KUMAR
Experimental and Clinical Transplantation - 2020;18(1):110-111
Early trials of tacrolimus in renal transplant recipients have not revealed hearing loss as an adverse effect. Here, we present a case report and a review of the literature of deafness after tacrolimus use. The review of the literature and our experience suggested that the possible reason for hearing loss could be due to an initiation of a sudden spike in the tacrolimus serum level, which was later worsened by its cumulative toxic effect.
